AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (AZN) received US FDA accelerated approval for ETCAMAH (camizestrant) plus a CDK4/6 inhibitor as 1st-line treatment for adult patients with HR‑positive, HER2‑negative, locally advanced or metastatic breast cancer with an emergent ESR1 mutation detected during aromatase inhibitor and CDK4/6 inhibitor therapy.
The decision is based on Phase III SERENA‑6, where ETCAMAH plus a CDK4/6 inhibitor reduced risk of disease progression or death by 56% versus an aromatase inhibitor plus CDK4/6 inhibitor (HR 0.44; median PFS 16.0 vs 9.2 months; p<0.00001). A pre‑planned analysis showed PFS2 of 25.7 vs 19.1 months (HR 0.63; p=0.00373) and overall survival data trending in favour of the ETCAMAH combination (HR 0.87) but still maturing.
The FDA simultaneously approved a companion ctDNA test to detect emerging ESR1 mutations and guide early therapy switch. Safety in SERENA‑6 was consistent with known profiles, though warnings highlight QTc prolongation, bradycardia, embryo‑fetal toxicity, common hematologic lab abnormalities and visual disturbances.
AstraZeneca (NASDAQ: AZN) has completed its previously announced exclusive global license agreement with Dizal Pharmaceutical for ZEGFROVY (sunvozertinib), an oral irreversible EGFR inhibitor for lung cancer, securing worldwide rights to develop and commercialize the medicine.
ZEGFROVY is approved in the US and China for 2nd-line treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations after progression on platinum-based chemotherapy. AstraZeneca plans a US launch in 4Q 2026. A supplemental NDA for 1st-line NSCLC has been accepted by the US FDA and submitted in China, supported by positive Phase III WU-KONG28 data, and the drug has Breakthrough Therapy Designation in both markets. Financial terms include a $600m upfront payment, up to $900m in milestones, and tiered royalties to Dizal, with no change to AstraZeneca’s 2026 financial guidance.
AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) plus pertuzumab has been approved in the EU as first-line treatment for adults with unresectable or metastatic HER2 positive breast cancer. The European Commission decision is based on phase 3 DESTINY-Breast09 data.
In 383 previously untreated HER2 positive metastatic patients, Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus taxane, trastuzumab and pertuzumab (THP) (hazard ratio 0.56; 95% CI 0.44–0.71). Median progression-free survival reached 40.7 months versus 26.9 months with THP, and confirmed objective response rates were 85.1% versus 78.6%. Safety was consistent with known profiles, though grade 3/4 neutropenia occurred in 24.8% and grade 5 events in 1.6% of patients.
Following this EU approval, AstraZeneca will pay Daiichi Sankyo a $100 million milestone, and Enhertu plus pertuzumab is now approved as first-line HER2 positive metastatic breast cancer therapy in more than 40 countries/regions.
AstraZeneca (LSE/STO/NYSE: AZN) reported positive high-level Phase III results from the randomized, double-blind CROSSING trial of TEZSPIRE (tezepelumab-ekko) in 368 patients aged 12-80 with eosinophilic esophagitis (EoE). TEZSPIRE, given subcutaneously every four weeks, achieved statistically significant and clinically meaningful improvements versus placebo in both co-primary endpoints—histologic remission and dysphagia symptoms (DSQ score)—at Week 24, sustained through Week 52 for both tested doses.
According to AstraZeneca, all key secondary endpoints, including longer-term histologic, endoscopic and inflammatory measures, were also met, and the safety profile was generally consistent with existing approved indications. TEZSPIRE, a first-in-class TSLP inhibitor already approved in severe asthma and CRSwNP, is being co-developed and co-commercialized globally with Amgen.
Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/NYSE:AZN) have dosed the first patient in the global phase 3 TROPION-Urothelial04 trial. The study evaluates Datroway (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus standard adjuvant options (durvalumab, nivolumab, or enfortumab vedotin plus pembrolizumab) in high-risk muscle invasive urothelial cancer (MIUC) after surgery.
The open-label, three-arm trial will randomize about 915 patients worldwide. The primary endpoint is investigator-assessed disease-free survival for Datroway plus rilvegostomig versus standard of care; key secondary endpoints include overall survival, multiple recurrence-free measures, patient-reported outcomes and safety. According to Daiichi Sankyo, the TIGIT component of rilvegostomig is derived from Compugen’s (Nasdaq/TASE:CGEN) clinical-stage antibody COM902.
Datroway, a TROP2-directed DXd antibody-drug conjugate, is already approved at 6 mg/kg in numerous countries for specific advanced breast cancer and EGFR-mutated NSCLC indications, and is being studied in more than 20 trials across lung, breast and urothelial cancers.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo reported that Phase III DESTINY-Lung04 met its primary endpoint, with ENHERTU (fam-trastuzumab deruxtecan-nxki) showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard 1st-line therapy (platinum-pemetrexed plus pembrolizumab) in unresectable, locally advanced or metastatic HER2‑mutant non-squamous NSCLC.
The trial will continue to assess overall survival and other secondary endpoints. According to AstraZeneca, the ENHERTU safety profile in DESTINY-Lung04 was generally consistent with its known risks, including interstitial lung disease/pneumonitis, neutropenia, left ventricular dysfunction, and embryo‑fetal toxicity, for which detailed boxed warnings and management guidelines are provided.
AstraZeneca (AZN) reported positive high-level results from the global Phase III SAFFRON trial evaluating TAGRISSO (osimertinib) plus savolitinib versus doublet platinum-based chemotherapy in 338 patients with EGFR‑mutated, locally advanced or metastatic NSCLC whose tumors had high MET overexpression or amplification and had progressed on prior TAGRISSO.
The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (primary endpoint) and overall survival versus chemotherapy. The safety profile was consistent with known profiles of each medicine, with no new safety findings. Data will be presented at a future medical meeting and shared with global regulators. TAGRISSO plus savolitinib is already approved in China in a related post‑EGFR‑TKI setting based on the SACHI Phase III trial.
AstraZeneca (AZN) and Daiichi Sankyo reported positive topline results from the phase 3 DESTINY-Lung04 trial, where Enhertu (trastuzumab deruxtecan) showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed chemotherapy plus pembrolizumab) as first-line treatment for unresectable, locally advanced or metastatic HER2 mutant non-squamous NSCLC.
The global, randomized trial enrolled 454 patients and will continue to assess secondary endpoints including overall survival. According to the companies, Enhertu’s safety profile in DESTINY-Lung04 was generally consistent with its known profile, with no new safety concerns identified. Data will be presented at an upcoming medical meeting and shared with global regulatory authorities. Enhertu is already approved in numerous countries for previously treated HER2 mutant metastatic NSCLC and multiple HER2-driven tumors.
SOPHiA GENETICS (Nasdaq: SOPH) announced a new multi-year global collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The agreement will advance two CDx programs using SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities.
According to SOPHiA GENETICS, its Solid Tumor application will be developed into a decentralized CDx, and its Hematological Oncology application will be developed and validated to support a CDx program for patients with blood cancer. The CDx solutions are intended to combine accurate biomarker detection with rapid, global deployment via the cloud-based SOPHiA DDM platform and the SOPHiA DDM MaxCare Program, allowing local laboratories worldwide to run the same validated, AI-powered analysis. SOPHiA GENETICS highlights that its technology-agnostic network connects more than 1,000 institutions across over 75 countries, aiming to expand access to innovative oncology treatments and support informed clinical decision-making in multiple healthcare systems.
AstraZeneca (AZN) and Daiichi Sankyo received European Commission approval for Datroway (datopotamab deruxtecan) as first-line monotherapy for adults with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Approval is based on the phase 3 TROPION-Breast02 trial, where Datroway improved median overall survival by 5.0 months versus chemotherapy (23.7 vs 18.7 months; HR=0.79; p=0.0291) and reduced risk of disease progression or death by 43% (HR=0.57; p<0.0001). Median progression-free survival was 10.8 vs 5.6 months, and objective response rate was 62.5% vs 29.3% with chemotherapy. Datroway is now approved in the EU for two breast cancer indications and is the only TROP2-directed ADC in the EU with demonstrated overall survival benefit in first-line metastatic TNBC, according to Daiichi Sankyo.